New drug candidate offers hope for patients with NRAS-driven melanoma

A Huntsman Cancer Institute team at the University of Utah reports that daraxonrasib, a targeted RAS inhibitor, could offer a new treatment route for a subset of melanoma patients whose tumors are driven by NRAS mutations. The work addresses an ongoing clinical gap: effective targeted options for NRAS-mutant metastatic melanoma have been limited, leaving many patients with fewer durable choices after immunotherapy.

NRAS-driven melanoma is fueled by altered NRAS signaling, a pathway that turns cancer-promoting cellular programs on. Daraxonrasib was developed by Revolution Medicines to interfere with RAS proteins, aiming to suppress the upstream signaling that supports tumor growth and survival.

The findings build on daraxonrasib’s earlier performance in metastatic pancreatic cancer, where a Phase 3 trial reported a substantial survival benefit. That clinical momentum, coupled with preclinical melanoma results, helped motivate deeper investigation into whether the same pathway disruption could translate to NRAS-driven skin cancer.

Researchers tested daraxonrasib across multiple preclinical models, including melanoma samples derived from patients. In these settings, the drug showed strong responsiveness, with tumor shrinkage observed—an outcome that is described as uncommon in NRAS-driven systems.

Senior author Martin McMahon, PhD, emphasizes that these data support the potential future clinical utility of daraxonrasib for NRAS-mutant melanoma. First author Mona Foth, PhD, adds that the observed responses suggest the approach could ultimately become a patient therapy capable of altering disease trajectories.

The study also explored how tumors may escape pathway inhibition. As is typical for targeted treatments, some models developed resistance to daraxonrasib. Resistance was linked to changes downstream of RAS involving MEK1, as well as reduced cyclophilin A expression, which is implicated in enabling daraxonrasib’s inhibitory action on RAS proteins.

These resistance mechanisms point to a practical next step: combination strategies. McMahon indicates that future work will test drug pairings built on a daraxonrasib backbone, with the goal of increasing both the depth and durability of responses.

The team is now aiming to move toward clinical evaluation, targeting patients who cannot receive immunotherapy or whose disease does not respond. If successful, daraxonrasib-based regimens could extend the therapeutic landscape for patients with NRAS-mutant metastatic melanoma.